Effect of tumor necrosis factor inhibitors on spinal radiographic progression in patients with ankylosing spondylitis

被引:14
作者
Jeong, Hyemin [1 ]
Eun, Yeong Hee [2 ]
Kim, In Young [2 ]
Park, Eun-Jung [3 ]
Kim, Hyungjin [2 ]
Lee, Jaejoon [2 ]
Jeon, Chan Hong [1 ]
Koh, Eun-Mi [2 ]
Cha, Hoon-Suk [2 ]
机构
[1] Soonchunhyang Univ Hosp, Dept Internal Med, Div Rheumatol, Bucheon, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Rheumatol,Dept Med, 50 Irwon Dong, Seoul 135710, South Korea
[3] Jeju Natl Univ Hosp, Dept Med, Jeju, South Korea
关键词
ankylosing spondylitis; spondyloarthritis; tumor necrosis factor; KOREAN SPONDYLOARTHROPATHY REGISTRY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PLACEBO-CONTROLLED TRIAL; SERUM LEPTIN LEVELS; BONE-FORMATION; AXIAL SPONDYLOARTHRITIS; DISEASE MODIFICATION; ANTIBODY INFLIXIMAB; DOUBLE-BLIND; INFLAMMATION;
D O I
10.1111/1756-185X.13270
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimTo evaluate the effect of tumor necrosis factor inhibitors (TNFi) on spinal radiographic progression in patients with ankylosing spondylitis (AS). MethodsSubjects were selected from patients at a single tertiary hospital between 1995 and 2014. Patients who used TNFi with baseline and paired follow-up radiographic data with a minimum interval of 2years were included. Time to start TNFi was defined as the time from symptom onset to the start of TNFi use. TNFi index was defined as the ratio of the period of TNFi use to the entire period of disease. Radiographic damage was assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). Univariable and multivariable linear regression analyses were used to identify factors associated with radiographic progression. ResultsA total of 151 patients were included in the analysis. Seventeen (11.3%) patients were female and mean mSASSS/year was 1.01 units/year. Mean X-ray follow-up duration was 102.954.9months. Mean time from symptom onset to start of TNFi use was 104.8 +/- 83.6months (median 84months) and mean TNFi index was 42.9 +/- 23.8% (median 40.9%). In multivariable analysis, initial mSASSS, initial C-reactive protein, body mass index, current smoker, and delayed start of TNFi use were associated with radiographic progression. Presence of peripheral arthritis and the TNFi index were negatively associated with radiographic progression. ConclusionsA delay in starting TNFi use and low TNFi index were associated with radiographic progression. Early and long-term use of TNFi appear to reduce spinal radiographic progression in patients with AS.
引用
收藏
页码:1098 / 1105
页数:8
相关论文
共 43 条
[1]   Determinants of Early Radiographic Progression in Ankylosing Spondylitis [J].
Atagunduz, Pamir ;
Aydin, Sibel Zehra ;
Bahadir, Cengiz ;
Erer, Burak ;
Direskeneli, Haner .
JOURNAL OF RHEUMATOLOGY, 2010, 37 (11) :2356-2361
[2]   Clinical features of adult-onset ankylosing spondylitis in Korean patients: patients with peripheral joint disease (PJD) have less severe spinal disease course than those without PJD [J].
Baek, HJ ;
Shin, KC ;
Lee, YJ ;
Kang, SW ;
Lee, EB ;
Yoo, CD ;
Song, YW .
RHEUMATOLOGY, 2004, 43 (12) :1526-1531
[3]   Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-α antibody infliximab [J].
Baraliakos, X. ;
Listing, J. ;
Brandt, J. ;
Haibel, H. ;
Rudwaleit, M. ;
Sieper, J. ;
Braun, J. .
RHEUMATOLOGY, 2007, 46 (09) :1450-1453
[4]   Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor a antibody infliximab [J].
Baraliakos, X ;
Listing, J ;
Rudwaleit, M ;
Brandt, J ;
Sieper, J ;
Braun, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1462-1466
[5]   Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis [J].
Baraliakos, Xenofon ;
Haibel, Hildrun ;
Listing, Joachim ;
Sieper, Joachim ;
Braun, Juergen .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (04) :710-715
[6]   The relationship between inflammation and new bone formation in patients with ankylosing spondylitis [J].
Baraliakos, Xenofon ;
Listing, Joachim ;
Rudwaleit, Martin ;
Sieper, Joachim ;
Braun, Juergen .
ARTHRITIS RESEARCH & THERAPY, 2008, 10 (05)
[7]   The Natural Course of Radiographic Progression in Ankylosing Spondylitis - Evidence for Major Individual Variations in a Large Proportion of Patients [J].
Baraliakos, Xenofon ;
Listing, Joachim ;
von der Recke, Anna ;
Braun, Jurgen .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (05) :997-1002
[8]   Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis -: An open, observational, extension study of a three-month, randomized, placebo-controlled trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Burmester, G ;
Golder, W ;
Gromnica-Ihle, E ;
Kellner, H ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Reddig, J ;
Sieper, J .
ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2224-2233
[9]   Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab -: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study [J].
Braun, J ;
Landewé, R ;
Hermann, KGA ;
Han, J ;
Yan, S ;
Williamson, P ;
van der Heijde, D .
ARTHRITIS AND RHEUMATISM, 2006, 54 (05) :1646-1652
[10]   The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial [J].
Braun, Juergen ;
Baraliakos, Xenofon ;
Hermann, Kay-Geert A. ;
Deodhar, Atul ;
van der Heijde, Desiree ;
Inman, Robert ;
Beutler, Anna ;
Zhou, Yiying ;
Xu, Stephen ;
Hsu, Benjamin .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (06) :1107-1113